| Literature DB >> 25946251 |
Daniel Silqueira Martins Guimarães1, Amanda Luisa da Fonseca1, Ronan Batista2, Moacyr Comar Junior3, Alaíde Braga de Oliveira4, Alex Gutterres Taranto5, Fernando de Pilla Varotti1.
Abstract
Malaria is responsible for more deaths around the world than any other parasitic disease. Due to the emergence of strains that are resistant to the current chemotherapeutic antimalarial arsenal, the search for new antimalarial drugs remains urgent though hampered by a lack of knowledge regarding the molecular mechanisms of artemisinin resistance. Semisynthetic compounds derived from diterpenes from the medicinal plant Wedelia paludosa were tested in silico against the Plasmodium falciparum Ca2+-ATPase, PfATP6. This protein was constructed by comparative modelling using the three-dimensional structure of a homologous protein, 1IWO, as a scaffold. Compound 21 showed the best docking scores, indicating a better interaction with PfATP6 than that of thapsigargin, the natural inhibitor. Inhibition of PfATP6 by diterpene compounds could promote a change in calcium homeostasis, leading to parasite death. These data suggest PfATP6 as a potential target for the antimalarial ent-kaurane diterpenes.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25946251 PMCID: PMC4489458 DOI: 10.1590/0074-02760140415
Source DB: PubMed Journal: Mem Inst Oswaldo Cruz ISSN: 0074-0276 Impact factor: 2.743
Fig. 1: three-dimensional structure of the mammalian Ca2+-ATPase 1IWO (A) and parasite PfATP6 model (B).
Rigid and flexible binding energy (Kcal/mol) of molecular docking between ent-kaurane diterpenes (8, 9 and 21) and thapsigargin against PfATP6 and 1IWO
| Compounds | 1IWO | PfATP6 | 1IWO | PfATP6 | |
|---|---|---|---|---|---|
|
|
| ||||
| Rigid | Flexible | ||||
| 8 | -7.6 | -7.7 | -7.1 | -6.6 | |
| 9 | -7.6 | -7.8 | -6.6 | -6.3 | |
| 21 | -9.5 | -8.4 | -7.4 | -6.8 | |
| Thapsigargin | -7.7 | -7.2 | -5.8 | -4.7 | |
Fig. 2: interactions of thapsigargin (A) and ent-kaurane diterpene 21 (B) with the PfATP6 binding site.
Grid box size and position for both enzymes models
| Centre position | Box size | ||||||
|---|---|---|---|---|---|---|---|
| x | y | z | x | y | z | ||
| 1IWO | -5.077 | -47.902 | 8.882 | 28 | 26 | 30 | |
| PfATP | -4.857 | -24.528 | 7.832 | 26 | 32 | 28 | |
Flexible amino acids of the active sites from the mammalian and parasite enzymes
| 1IWO | PfATP6 | |||||
|---|---|---|---|---|---|---|
| Residue | Symbol | Position | Residue | Symbol | Position | |
| Leucine | LEU | 253 | Isoleucine | ILE | 251 | |
| Glutamate | GLU | 255 | Leucine | LEU | 253 | |
| Phenylalanine | PHE | 256 | Phenylalanine | PHE | 254 | |
| Glutamine | GLN | 259 | Glutamine | GLN | 257 | |
| Leucine | LEU | 260 | Leucine | LEU | 258 | |
| Valine | VAL | 263 | Isoleucine | ILE | 261 | |
| Isoleucine | ILE | 761 | Isoleucine | ILE | 748 | |
| Isoleucine | ILE | 765 | Isoleucine | ILE | 752 | |
| Aspartate | ASN | 768 | Aspartate | ASN | 755 | |
| Valine | VAL | 769 | Isoleucine | ILE | 756 | |
| Valine | VAL | 772 | Valine | VAL | 759 | |
| Valine | VAL | 773 | Phenylalanine | PHE | 763 | |
| Phenylalanine | PHE | 776 | Leucine | LEU | 815 | |
| Leucine | LEU | 828 | Isoleucine | ILE | 816 | |
| Isoleucine | ILE | 829 | Leucine | LEU | 821 | |
| Phenylalanine | PHE | 834 | Tyrosine | TYR | 824 | |
| Tyrosine | TYR | 837 | Isoleucine | ILE | 825 | |
| Methionine | MET | 838 | - | - | - | |